CD19 and diffuse large B-cell lymphoma: The first United States Food and Drug Administration (FDA)-approved applications of CAR T-cell therapy occurred in 2017 with the release of the commercial CD19-directed CAR T-cell therapies Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) that are used to treat B-cell ALL and diffuse large B-cell lymphoma (DLBCL) [7, 10, 11].